

#### Detailed Guide to Covered Preventive Services

Service	Patient	Procedure Code	Procedure Description	Related Diagnosis Code(s)	Diagnosis Code Description
Routine general medical exam	All	99201	Office visit or other outpatient visit for the evaluation and management of a new patient, which requires these three key components: a problem focused history; a problem focused examination; and straightforward medical decision making	V70.0 (Effective 8/1/2011)	Routine general medical exam
		99202	Office visit or other outpatient visit for the evaluation and management of a new patient, which requires these three key components: an expanded problem focused history; an expanded problem focused examination; and straightforward medical decision making		
		99203	Office visit or other outpatient visit for the evaluation and management of a new patient, which requires these three key components: a detailed history; a detailed examination; and medical decision making of low complexity		
		99204	Office visit or other outpatient visit for the evaluation and management of a new patient, which requires these three key components: a comprehensive history; a comprehensive examination; and medical decision making of moderate complexity		
		99205	Office visit or other outpatient visit for the evaluation and management of a new patient, which requires these three key components: a comprehensive history; a comprehensive examination; and medical decision making of high complexity.		
		99211	Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician. Usually, the presenting problem(s) are minimal. Typically, 5 minutes are spent performing or supervising these services		
		99212	Office or other outpatient visit for the evaluation and management of an established patient, which requires at least two of these three key components: a problem focused history; a problem focused examination; straightforward medical decision making		

Routine	All	99213	Office or other outpatient visit for the evaluation and management of an	V70.0	Routine general
general medical exam, cont.			established patient, which requires at least two of these three key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity	(Effective 8/1/2011)	medical exam
		99214	Office or other outpatient visit for the evaluation and management of an established patient, which requires at least two of these three key components: a detailed history; a detailed examination; medical decision making of moderate complexity		
		99215	Office or other outpatient visit for the evaluation and management of an established patient, which requires at least two of these three key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity		
		99383	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; late childhood (age 5 through 11 years)		
		99384	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; adolescent (age 12 through 17 years)		
		99385	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years		
		99386	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years		
		99387	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction in terventions, and the ordering of laboratory/diagnostic procedures, new patient; 65 years and older		
		99393	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years)		

Routine general medical exam, cont.		99394	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years)	V70.0 (Effective 8/1/2011)	Routine general medical exam
		99395	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years		
		99396	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years		
		99397	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 65 years and older		
		99401- 99404	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure)		

## Guide to Covered Preventive Services Additional Allowances for Assurant Health Customers



Service	Patient	Procedure Code	Procedure Description	Related Diagnosis Code(s)	Diagnosis Code Description
Miscellaneous	All children and	80050	General health panel	V70.0	Routine general medical exam
services	adults	80053	Comprehensive metabolic panel	V72 (2	
(Effective 7/2/2012)		81000-81003	Urinalysis	V72.62	Laboratory examination ordered as part of a routine general
77272012)		84443	Thyroid stimulating hormone (TSH)		medical examination
		85025	Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count		
Screening only Mammography	Covered annually. Note: See Breast C	ancer Screening via mar	mammography al	lowances for all reform plans.	
(Effective 1/1/2014 for reform METALLIC plans only)	Women age 40+	77052	Computer aided detection (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation, with or without digitization of film radiographic images; screening mammography	Any diagnosis code	
		77055	Mammography; unilateral		
		77056	Mammography; bilateral		
		77057	Screening mammography, bilateral (two view film study of each breast)	_	
		G0202	Screening mammography, producing direct digital image, bilateral, all views		
		Revenue Code 403	Screening Mammography		

Colorectal	Note: See Colorect	ectal Cancer Screening	under Adults for USPSTF standard colorectal scree	ning allowan	ices for all reform plans.
Cancer screening (Effective 1/1/2014	Adults ages 50 to 75	00810	Anesthesia for lower intestinal endoscopic procedures	211.3	Benign neoplasm of colon
		45300	Proctosigmoidoscopy, rigid; diagnostic	211.4	Benign neoplasm of rectum
for reform METALLIC		45305	Proctosigmoidoscopy, rigid; diagnostic, with biopsy		and anal canal  Anal and rectal polyp
plans only)		45308-45315	Proctosigmoidoscopy, rigid; diagnostic, with removal of tumor(s), polyp(s), or other lesion(s)	307.0	Anat and rectat potyp
		45320	Proctosigmoidoscopy, rigid; with ablation of tumor(s), polyp(s), or other lesion(s).		
		45330	Sigmoidoscopy, flexible; diagnostic		
		45331	Sigmoidoscopy, flexible; with biopsy, single or multiple		
		45333	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)		
		45338	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)		
		45339	Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s)		
		45341	Sigmoidoscopy, flexible; with endoscopic ultrasound exam		
		45342	Sigmoidoscopy, flexible; with transen- doscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy		
		45378	Colonoscopy, flexible; diagnostic		
		45380	Colonoscopy, flexible; with biopsy, single or multiple		
		45381	Colonoscopy, flexible, proximal to splenic flexure; with directed submucosal injection(s), any substance		
		45382	Colonoscopy, flexible, proximal to splenic flexure; with control of bleeding (e.g., injection, bipolar cautery, unipolar cautery, laser, heater probe, stapler, plasma coagulator)		
		45383	Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s)		

Colorectal cancer	Adults ages 50 to 75	45384	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)
screening, cont.		45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)
		45391	Colonoscopy, flexible; with endoscopic ultrasound exam
		45392	Colonoscopy, flexible, with transendoscopic ultrasound guided intramural or transmural fine needle aspiration
		G0104	Colorectal cancer screening; flexible sigmoidoscopy
		G0105	Colorectal cancer screening; colonoscopy on individual at high risk
		G0106	Colorectal cancer screening; screening sigmoidoscopy, barium enema
		G0120	Colorectal cancer screening; screening colonoscopy, barium enema
		G0121	Colorectal cancer screening; colonoscopy on individual not high risk

### Guide to Covered Preventive Services Immunizations for Adults



	Patient	Procedure Code	Procedure Description
Administration	All adults	90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); one vaccine
		90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine
		90473	Immunization administration by intranasal or oral route; one vaccine
		90474	Immunization administration by intranasal or oral route; each additional vaccine
Hepatitis A	All adults	90632	Hepatitis A vaccine, adult dosage, for intramuscular use
	All adults	90636	Hepatitis A and B vaccine, adult dosage, for intramuscular use
Hepatitis B	All adults	90636	Hepatitis A and B vaccine, adult dosage, for intramuscular use
		90740	Hepatitus B vaccine, dialysis or immunosuppressed patient dosage (3-dose schedule), for intramuscular use
	All adults	90746	Hepatitis B vaccine adult dosage
		90747	Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4-dose schedule), for intramuscular use
Human Papillomavirus	Females age 9 through 26 years	90649	Human papillomavirus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3-dose schedule, for intramuscular use
(HPV)	Males age 11 through 26 years (Effective 1/1/2012 for all reform plans)	90650	Human papillomavirus (HPV) vaccine, types 16, 18 (bivalent), 3-dose schedule, for intramuscular use

Influenza	All adults	90654	Influenza virus vaccine, split virus, preservative free, for intradermal use
		90656	Influenza virus vaccine, split virus, preservative free, when administered to individuals three years and older, for intramuscular use
		90658	Influenza virus vaccine, split virus, when administered to individuals three years of age and older, for intramuscular use
		90660	Influenza virus vaccine, live, for intranasal use
		90661	(Effective 11/20/2012) — Influenza virus vaccine, derived from cell cultures, subunit, preservative and antibiotic free, for intramuscular use
		90662	Influenza virus vaccine, split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use (for Fluzone High-Dose). (This code is for age 65 and older).
		90672	(Effective 1/1/2013) — Influenza virus vaccine, quadrivalent, live, for intranasal use
		90673	(Effective 1/1/2014) — Influenza virus vaccine, trivalent, derived from recombinant DNA (RIV3), hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
		90686	(Effective 1/1/2013) — Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to individuals 3 years of age and older, for intramuscular use
		90688	(Effective 8/16/2013) — Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use
		Q2034	(Effective 7/1/2012) — Influenza virus vaccine, split virus, for intramuscular use (Agriflu) Sipuleucel-t, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion
		Q2035	(Effective 7/1/2012) — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Afluria)
		Q2036	(Effective 7/1/2012) — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Flulaval)
		Q2037	(Effective 7/1/2012) — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluvirin)
		Q2038	(Effective 7/1/2012) — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone)
		Q2039	(Effective 7/1/2012) — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (not otherwise specified)
Measles, Mumps	All adults	90704	Mumps virus vaccine, live, for subcutaneous use
and Rubella		90705	Measles virus vaccine, live, for subcutaneous use
		90706	Rubella virus vaccine, live, for subcutaneous use
		90707	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use
		90708	Measles and rubella virus vaccine (MMR), live, for subcutaneous use
		90710	Measles, Mumps and Rubella and Varicella (MMRV), live, for subcutaneous use

Meningococcal	All adults	90733	Meningococcal polysaccharide vaccine, (any group(s)), for subcutaneous use
(meningitis)		90734	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetravalent), for intramuscular use
Pneumococcal	All adults	90669	Pneumococcal conjugate vaccine, 7 valent, for intramuscular use
(pneumonia)		90670	Pneumococcal conjugate vaccine, 13 valent, for intramuscular use
	All adults 90732		Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use
Tetanus,	All adults and children	90701	Diphtheria, tetanus and whole cellular pertussis vaccine (DTP), for intramuscular use
Diptheria,	age 7 and older	90703	Tetanus toxoid adsorbed, for intramuscular use
Pertussis		90714	Tetanus and diphtheria (Td) adsorbed, preservative free, when administered to individuals 7 years or older, for intramuscular use
		90715	Tetanus, diphtheria and acellular pertussis vaccine(Tdap), when administered to individuals 7 years or older, for intramuscular use
		90718	Tetanus and diphtheria toxoids (Td) adsorbed when administered to individuals 7 years or older, for intramuscular use.
		90719	Diphtheria toxoid, for intramuscular use
Varicella	All adults	90710	Measles, Mumps and Rubella and Varicella (MMRV), live, for subcutaneous use
(chicken pox)		90716	Varicella virus vaccine, live, for subcutaneous use
Zoster (shingles)	Age 60 and older	90736	Zoster (shingles) vaccine, live, for subcutaneous injection

#### Guide to Covered Preventive Services Adults



Service	Patient	Procedure Code	Procedure Codes		
Abdominal aortic aneurysm	Men who have ever smoked — ages 65-75	76775	Ultrasound of the abdominal aorta	V70.0	Routine general medical exam
screening		76770	(Effective 1/1/2013) — Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documention; complete	V70.8-V70.9	Other and unspecified general medical examination
		G0389		V82.9	Screening for unspecified condition
			Ultrasound B-scan and/or real time with image documentation; for abdominal aortic aneurysm screening	305.1	Tobacco use disorder
				V15.82	History of tobacco use
				V81.2	Special screening; other and unspecified cardiovascular conditions

Alcohol misuse screening and counseling	All adults age 18+	90785	(Effective 1/1/2013) — Interactive complexity (list separately in addition to the code for primary procedure)	305.00-305.03 655.40-655.43	Known or suspected fetal		
		90791-90792	(Effective 1/1/2013) — Psychiatric diagnostic evaluation		abnormality affecting management of mother; suspected damage to fetus from other disease in mother		
		90801-90815	Psychotherapy interviews/visits — outpatient				
		90832-90838	(Effective 1/1/2013) — Psychotherapy visits with patient and/or family		(includes alcohol addiction)		
		99201-99215	Office visits	V22.0 - V22.2	(Effective 9/1/2013) —		
		99401-99404	Preventive medicine counseling		Normal pregnancy		
		99408-99409	Alcohol and/or substance (other than tobacco) abuse structured screening, and brief intervention services	V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy		
		99411-99412	Preventive medicine counseling, group G0396-G0397 Alcohol and/or substance (other than tobacco) abuse structured assessment and intervention	V65.42	(Effective 1/1/2013) — Counseling on substance use and abuse		
		G0442	Annual alcohol misuse screening, 15 minutes	760.71	Noxious influences affecting fetus or newborn via placenta or breast milk; alcohol		
		G0443	Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes				
		H0001	Alcohol and/or drug assessment				
		H0005	Alcohol and/or drug services; group counseling	V70.0	Routine general medical		
		H0006	Alcohol and/or drug services; case management	(Effective	exams		
		H0015	Alcohol and/or drug services; intensive outpatient, including assessment, counseling; crisis intervention, and activity therapies or education	8/1/2011) V79.1	(Effective 1/1/2013) — Special screening; alcoholism		
		H0049	Alcohol and/or drug screening		special servering, alconotism		
		H0050	Alcohol and/or drug services, brief intervention, per 15 minutes				
		T1006-T1007	Alcohol and/or substance abuse services				
		T1012	Alcohol and/or substance abuse services				
Aspirin for prevention of cardiovascular disease	Men ages 45-79 Women ages 55-79	No codes assoc	iated with this recommendation — Over-the-counter a	spirin			

Blood pressure screening (USP- STF)	All adults age 18+	No code as is in	cluded as part of office visit; not separately billable		
BRCA genetic counseling &	Women at in- creased risk for	81211 - 81217	(Effective 2/20/2013) — BRCA1 and/or BRCA2 gene analysis	V16.3 V16.41	Family history of breast cancer
testing	the BRCA genetic mutation	96040	Medical genetics and genetic counseling services, each 30 minutes, face-to-face with patient/family		Family history of ovarian
		99201-99215	Office visits		cancer
		99385-99387	Initial preventive visit — ages 18-65+ years	V22.0 - V22.2	(Effective 9/1/2013) —
		99395-99397	Periodic preventive visit — ages 18-65+ years		Normal pregnancy
		99401-99404	Preventive medicine counseling	V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy
		S0265		V70.0 (Effective	Routine general medical exams
			Genetic counseling, under physician supervision, each 15 minutes	8/1/2011) V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear
					V82.71
				V82.79	Other genetic screening
				V84.01	Genetic susceptibility to malignant neoplasm of breast
				V84.02	Genetic susceptibility to malignant neoplasm of ovary

9	Adult women at	99201-99215	Office visits	V07.39	Other prophylactic
chemopreven-	high risk for breast	99385-99387	Initial preventive visit — ages 18-65+ years		chemotherapy
tion for women at high risk for breast cancer	cancer	99395-99397	Periodic preventive visit — ages 18-65+ years	V16.3	Family history of breast cancer
				V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy
				V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy
		99401-99404	Preventive medicine counseling	V70.0 (Effective 8/1/2011)	Routine general medical exams
			Trevenerve medicine counsetting	V82.71	Screening for genetic disease carrier status
				V82.79	Other genetic screening
				V84.01	Genetic susceptibility to malignant neoplasm of breast

Breast cancer screening via mammography	Covered annually				
	Women age 40+	77052	Computer aided detection (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation, with or without digitization of film radiographic images; screening mammography	V16.3 V22.0 - V22.2	Family history of breast cancer  (Effective 9/1/2013) — Normal pregnancy
		77055	Mammography; unilateral	V22 0 V22 0	(566 1: 0.44 (2042)
		77056	Mammography; bilateral	V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy
		77057	Screening mammography, bilateral (two view film study of each breast)	V76.10	Special screening for
		99201-99215	Office visits		malignant neoplasm; breast,
		99386 — 99387	Initial preventive visit — ages 40-65+ years		unspecified
		99396 — 99397	Periodic preventive visit — ages 40-65+ years	V76.11	Special screening for malignant neoplasm; breast, high-risk patient
		99401-99404	Preventive medicine counseling		
		G0202	Screening mammography, producing direct digital image, bilateral, all views		
		Revenue code 403	Screening mammography		Special screening for malignant neoplasm; breast, other screening mammogram
				V76.19	Special screening for malignant neoplasm; breast, other screening breast exam
				V70.0 (Effective 8/1/2011)	Routine general medical examination at a health care facility
				V84.01	Genetic susceptibility to malignant neoplasm of breast

Cervical cancer screening via Pap test		87620-87622	- if visit also billed, then this code is inclusive to visit.	V72.31	Companied average with
	Sexually active women with cervix	8/620-8/622	(Effective 8/1/2012 for reform policies with policy effective dates of 8/1/2012 - 12/31/2012. Effective 1/1/2013 for all other reform policies) Infectious agent detection by nucleic acid; human	V72.31	Gynecological exam with or without Pap smear  (Effective 8/1/2012
			papillomavirus	_	for reform policies with
		88141-88155	Cytopathology, cervical or vaginal		policy effective dates of 8/1/2012 - 12/31/2012.
		88164-88167	Cytopathology, slides, cervical or vaginal		Effective 1/1/2013 for
		88174-88175	Cytopathology, cervical or vaginal		all other reform policies)
		99201-99215	Office visits		Special screening exam for viral & chlamydial diseases; HPV  (Effective 8/1/2012 for reform policies with policy effective dates of 8/1/2012 - 12/31/2012. Effective 1/1/2013 for all other reform policies) Special screening exam for viral & chlamydial diseases; other specified
		99385-99387	Initial preventive visit — ages 18-65+ years		
		99395-99397	Periodic preventive visit — ages 18-65+ years	V73.89	
		99401-99404	Preventive medicine counseling		
		G0101*	Cervical or vaginal cancer screening; pelvic and clinical breast exam		
		G0123-G0124	Screening cytopathology, cervical or vaginal		
		G0141-G0148	Screening cytopathology smears, cervical or vaginal		
		P3000-P3001	Screening Pap smear, cervical or vaginal		
		Q0091*	Screening Pap smear, obtaining, preparing and conveyance to lab.		
		S0610*	Annual gynecological exam, new patient	V76.2	Special screening for
		S0612*	Annual gynecological exam, established patient	770.2	malignant neoplasm; cervix
				V70.0 (Effective 8/1/2011)	Routine general medical examination at a health care facility
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination

Breastfeeding counseling	All pregnant women and women	99078	Physician educational services rendered to patients in group setting	V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy
	with newborns	99201-99215	Office visits	V22 0 V22 0	(5(5, 1), 0 (4 (2042)
		99401-99404	Preventive medicine counseling	V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy
		S9443	Lactation classes, nonphysician provider	V24.1	Lactating mother (supervision of lactation)
				V70.0 (Effective 8/1/2011)	Routine general medical exams
Chlamydia	All women age 24	86631-86632	Antibody immunoassay; chlamydia	V73.88	Special screening exam for
infection	and younger who	87110	Culture, chlamydia, any source	V73.98  V70.0 (Effective 8/1/2011)	other specified chlamydial diseases  Special screening exam for unspecified chlamydial diseases
screening	are sexually active	87270	Infectious agent detection by immunofluorescent technique; chlamydia trachomatis		
	Women age 24+	87320	Infectious agent antigen detection by enzyme immunoassay technique; chlamydia trachomatis		
	who are at in- creased risk	87490-87492	Infectious agent antigen detection by nucleic acid (DNA or RNA); chlamydia trachomatis		Routine general medical
		87810	Infectious agent antigen detection by immunoassay with direct optical observation; chlamydia trachomatis		examination at a health care facility
		99201-99215	Office visits	V72.31 (Effective	Gynecological exam with or without pap smear
		99385-99387	Initial preventive visit — ages 18-65+ years	2/1/2014)	
		99395-99397	Periodic preventive visit — ages 18-65+ years	V72 (2	I de contra de c
		99401-99404	Preventive medicine counseling	V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination

Colorectal cancer screening	Adults ages 50 to 75	00810	Anesthesia for lower intestinal endoscopic procedures	V16.0	Family history of malignant neoplasm; gastrointestinal
		45300	Proctosigmoidoscopy, rigid; diagnostic		tract
		45305	Proctosigmoidoscopy, rigid; diagnostic, with biopsy	V18.51	Family history of certain other specific conditions; digestive disorders, colonic
		45308-45315	Proctosigmoidoscopy, rigid; diagnostic, with removal of tumor(s), polyp(s), or other lesion(s)	V22.0 - V22.2	
		45320	Proctosigmoidoscopy, rigid; with ablation of tumor(s), polyp(s), or other lesion(s).		polyps
		45330	Sigmoidoscopy, flexible; diagnostic		(Effective 9/1/2013) — Normal pregnancy
		45331	Sigmoidoscopy, flexible; with biopsy, single or multiple	V23.0 - V23.9	(Effective 9/1/2013) —
		45333	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery	. V23.0 - V23.9	High-risk pregnancy
	• 453. • 453.	45338	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	(Effective 8/1/2011) examination at a hea facility (physician onlow V76.41 Special screening for nant neoplasm; other	Routine general medical examination at a health care
		45339	Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique		Special screening for malignant neoplasm; other sites, rectum
		45341	Sigmoidoscopy, flexible; with endoscopic ultrasound exam	V76.50	Special screening for malig- nant neoplasm; intestine, unspecified
		45342	Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy		
		45378	Colonoscopy, flexible; diagnostic	V76.51	Special screening for malig-
		45380	Colonoscopy, flexible; with biopsy, single or multiple	V72.62 (Effective 5/1/2012)	nant neoplasm; intestine, colon
		45381	Colonoscopy, flexible, proximal to splenic flexure; with directed submucosal injection(s), any substance		Laboratory examination ordered as part of a routine general medical examination
		45382	Colonoscopy, flexible, proximal to splenic flexure; with control of bleeding (e.g., injection, bipolar cautery, unipolar cautery, laser, heater probe, stapler, plasma coagulator)	, ,	
		45383	Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s)		

If billed with Modifier -33 or -PT, allowable with ANY diagnosis.

Colorectal cancer screening, cont.	Adults ages 50 to 75	45384 — 45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <i>If billed with Modifier</i> -33 or -PT, allowable with ANY diagnosis	
		45391	Colonoscopy, flexible; with endoscopic ultrasound exam <i>If billed with Modifier -33 or -PT</i> , allowable with ANY diagnosis	
		45392	Colonoscopy, flexible, with transendoscopic ultrasound guided intramural or transmural fine needle aspiration <i>If billed with Modifier -33 or -PT, allowable with ANY diagnosis</i>	
		82270	Blood, occult; feces	
		82272	Blood, occult; feces	
		82274	Blood, occult; fecal hemoglobin	
		88304-88305	(Effective 1/1/2013) — Surgical pathology	
		99201-99215	Office visits	
		99386 — 99387	Initial preventive visit — ages 40-65+ years	
		99396 — 99397	Periodic preventive visit — ages 40-65+ years	
		99401-99404	Preventive medicine counseling	
		G0104 — G0106	Colorectal cancer screening If billed with Modifier -33 or -PT, allowable with ANY diagnosis	
		G0120	Colorectal cancer screening; screening colonoscopy, barium enema <i>If billed with Modifier -33 or -PT</i> , allowable with ANY diagnosis	
		G0121	Colorectal cancer screening; colonoscopy on individual not high risk <i>If billed with Modifier -33</i> or -PT, allowable with ANY diagnosis	
		G0122	Colorectal cancer screening; barium enema	
		G0328	Colorectal cancer screening; fecal occult blood test	

Depression screening	Benefits are for the screening related to the treatment of depression, but not for the treatment itself. Please refer to your policy to determine coverage for the treatment of depression.						
	All adults	90785	(Effective 1/1/2013) — Interactive complexity (list separately in addition to the code for primary procedure)	V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy		
		90791-90792	(Effective 1/1/2013) — Psychiatric diagnostic evaluation	V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy		
		90801-90802	Psychiatric diagnostic interview examination	V70.0	Routine general medical		
		96101-96103	Psychological testing	(Effective	exams		
		96116	Neurobehavioral status exam	8/1/2011)			
		96118-96120	Neuropsychological testing	V79.0	Special screening for mental		
		96150-96151	Health and behavior assessment	779.0	disorders and developmental		
		99201-99215	Office visits		handicaps; depression		
		99401-99404	Preventive medicine counseling				
		G0444	Annual depression screening, 15 minutes				
		H0002	Behavioral health screening to determine eligibility for admission to treatment program				
		H0031	Mental health assessment, by nonphysician				

Type 2 diabetes	Adults with high	82947	Glucose; quantitative, blood	401.0-401.9	(Effective 1/1/2013) —
screening	blood pressure	82948	Glucose; blood, reagent strip		Essential hypertension
		82950	Glucose; post glucose dose	402.00-402.91	(Effective 1/1/2013) —
		82951	Glucose; tolerance test, 3 specimens		Hypertensive heart disease
		82952	Glucose; tolerance test, each additional specimen	403.00-403.91	(Effective 1/1/2013) -
		83036	Hemoglobin; glycosylated (A1C)		Hypertensive chronic kidney disease
		99201-99215	Office visits	404.00-404.93	
		99385-99387	Initial preventive visit — ages 18-65+ years	404.00-404.93	Hypertensive heart & chronic
		99395-99397	Periodic preventive visit — ages 18-65+ years		kidney disease
		99401-99404	Preventive medicine counseling	405.01	(Effective 1/1/2013) — Secondary hypertension; malignant renovascular
				405.09	(Effective 1/1/2013) — Secondary hypertension; malignant other
				405.11	(Effective 1/1/2013) — Secondary hypertension; benign renovascular
				405.19	(Effective 1/1/2013) — Secondary hypertension; benign other
				405.91	(Effective 1/1/2013) — Secondary hypertension; other renovascular
				405.99	Secondary hypertension; other
				V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy
				V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy
				V77.1	Special screening for endocrine, nutritional, metabolic, and immunity disorders; diabetes mellitus

Type 2 diabetes screening, cont.	Adults with high blood pressure, cont.	99401-99404, cont.	Preventive medicine counseling, cont.	V70.0 (Effective 8/1/2011)	Routine general medical examination at a health care facility
				V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
Folic acid supplementation	Adult women planning or capable of pregnancy	No codes assoc	iated with this recommendation — Over-the-counter f	folic acid supple	ments
Gonorrhea screening	All sexually active women who are at increased risk	87070	Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates	V74.5	Special screening exam for bacterial and spirochetal diseases; venereal disease
		87081	Culture, presumptive, pathogenic organisms, screening		B. C
		87590	Neisseria gonorrhoeae, direct probe technique	V70.0	Routine general medical examination at a health
		87591	Neisseria gonorrhoeae, amplified probe technique	(Effective 8/1/2011)	care facility
		87592	Neisseria gonorrhoeae, quantification		
		87850	(Effective 1/1/2014) — Neisseria gonorrhoeae, Infectious agent detection by immunoassay with direct optical observation	V72.31 (Effective – 2/1/2014)	Gynecological exam with or without pap smear
		99201-99215	Office visits	2/1/2014)	
		99385-99387	Initial preventive visit — ages 18-65+ years	V72.62	Laboratory examination
		99395-99397	Periodic preventive visit — ages 18-65+ years	(Effective 5/1/2012)	ordered as part of a routine general medical examination
		99401-99404	Preventive medicine counseling	3, 1, 2012)	50.0. at medical examination

Healthy diet	Healthy diet Adults with	96150-96151	Health and behavior assessment	V22.0 - V22.2	(Effective 9/1/2013) —
counseling	hyperlipidemia	96152-96154	Health and behavior intervention		Normal pregnancy
	and other known risk factors for	97802-97804	Medical nutrition therapy	V23.0 - V23.9	(Effective 9/1/2013) —
	cardiovascular and diet-related	99078	Physician educational services rendered to patients in group setting	723.3 723.7	High-risk pregnancy
	chronic diseases	99201-99215	Office visits	V65.3	Dietary surveillance and
		99385-99387	Initial preventive visit — ages 18-65+ years		counseling
		99395-99397	Periodic preventive visit — ages 18-65+ years	V69.1	Inappropriate diet and eating
		99401-99404	Preventive medicine counseling		habits
		99411-99412	(Effective 1/1/2013) — Preventive medicine counseling, group	V70.0	Routine general medical
		G0270-G0271	Medical nutrition therapy	(Effective 8/1/2011)	exams
		S9449	Weight management classes, nonphysician provider, per session		Special screening for
		S9452	Nutrition classes, nonphysician provider, per session		endocrine, nutritional,
		S9470	Nutritional counseling, dietitian visit		metabolic, and immunity disorders; obesity
				272.4	Disorders of lipoid metabolism; Other and unspecified hyperlipidemia

Hepatitis C screening (Effective		g one-time scree	or hepatitis C virus (HCV) infection in persons at high ening for HCV infection to adults born between 1945 an		
6/25/2014 for new business	All ages	86803	Hepatitis C antibody	042	Human immunodeficiency virus (HIV) disease
reform policies		86804	Hepatitis C antibody; confirmatory test		(int) discuse
with an effective date of 6/25/2014 or		87520	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique	079.52	Human immunodeficiency virus, type II (HIV-2)
later. Effective 1/1/2015 for all reform policies.)		87521	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed	286.0-286.9	Coagulation defects
reform poticies.)		87522	Infectious agent detection by nucleic acid (DNA or	304.00-305.93	Drug dependence and nondependent use of drugs
		0,022	RNA); hepatitis C, quantification, includes reverse transcription when performed	790.4	Nonspecific elevation of levels
		87902	Infectious agent genotype analysis by nucleic acid (DNA or RNA); hepatitis C virus		of transaminase or lactic acid dehydrogenase (LDH) (ALT)
				V01.7	Contact with or exposure to communicable diseases; other viral diseases
				V02.60	Carrier or suspected carrier of infectious diseases; viral hepatitis C carrier, unspecified
				V02.62	Carrier or suspected carrier of infectious diseases; hepatitis C carrier
				V42.0-V42.9	Organ or tissue replaced by transplant
				V45.11	Renal dialysis status
				V58.2	Blood transfusion, without reported diagnosis
				V59.01-V59.9	Donors (whole blood, stem cells, plasma, organs, tissues, semen)
				V69.2	Problems related to lifestyle; high-risk sexual behavior

Hepatitis C screening, cont.		V70.0	Routine general medical examination at a health care facility (This DX billed with one of above CPT codes is allowable ONCE per lifetime.)
		V72.62	Laboratory examination ordered as part of a routine general medical examination (This DX billed with one of above CPT codes is allowable ONCE per lifetime.)
		584.5-586	Renal failure

HIV screening	Adults at increased risk		Antibody; HTLV or HIV antibody, confirmatory test (e.g., Western Blot)	V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy
		86701-86703	Antibody; HIV-1 and/or HIV-2		9 (Effective 9/1/2013) — High-risk pregnancy
		87390	Infectious agent antigen detection by enzyme immunoassay technique; HIV-1	V23.0 - V23.9	
		87391	Infectious agent antigen detection by enzyme immunoassay technique; HIV-2	V69.2	Problems related to lifestyle; high-risk sexual behavior
		99201-99215	Office visits		
		99383-99387	Initial preventive visit — ages 5-65+ years	V69.8-V69.9	Problems related to lifestyle;
		99393-99397	Periodic preventive visit — ages 5-65+ years		other and unspecified problems related to lifestyle
		99401-99404	Preventive medicine counseling	V70.0	
					Routine general medical
		G0432	Infectious agent antibody detection by enzyme immunoassay technique, HIV-1 and/or HIV-2, screening	(Effective 8/1/2011)	examination at a health care facility  Gynecological exam with or without pap smear  Special screening exam for viral and chlamydial
				V72.31 (Effective 2/1/2014)	
		G0433	Infectious agent antibody detection by enzyme- linked immunoabsorbent assay technique, HIV-1 and/or HIV-2, screening		
		G0435	Infectious agent antibody detection by rapid	V73.89	
			antibody test, HIV-1 and/or HIV-2, screening		diseases; other specified
	S3645	HIV-1 antibody testing of oral mucosal transudate		viral diseases	
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination

Lipid disorders	Men and women	80061	Lipid panel	V22.0 - V22.2	(Effective 9/1/2013) —
screening	age 20+ if they are at increased risk	82465	Cholesterol, serum or whole blood, total		Normal pregnancy
	for coronary heart	83718	Lipoprotein, direct measurement; HDL cholesterol	V23.0 - V23.9	(Effective 9/1/2013) —
	disease	83721	Lipoprotein, direct measurement; LDL cholesterol		High-risk pregnancy
		99201-99215	Office visits		
		99385-99387	Initial preventive visit — ages 18-65+ years	V77.91	Special screening for endocrine, nutritional,
		99395-99397	Periodic preventive visit — ages 18-65+ years		metabolic, and immunity
		99401-99404	Preventive medicine counseling		disorders; lipoid disorders
				V70.0 (Effective 8/1/2011) V72.31 (Effective 2/1/2014)	Routine general medical examination at a health care facility  Gynecological exam with or without pap smear
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
Obesity	All adults	97802-97804	Medical nutrition therapy	278.00	Obesity, unspecified
screening, counseling		99078	Physician educational services rendered to patients in group setting	278.01	Morbid obesity
and behavioral interventions		99201-99215	Office visits	V22.0 - V22.2	(Effective 9/1/2013) —
		99385-99387	Initial preventive visit — ages 18-65+ years		Normal pregnancy
		99395-99397	Periodic preventive visit — ages 18-65+ years		(566 0 (4 (9949)
		99401-99404	Preventive medicine counseling	V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy
		99411-99412	Preventive medicine counseling, group	_	mg. risk pregnancy
		G0447	Face-to-face behavioral counseling for obesity, 15 minutes.	V70.0 (Effective	Routine general medical examination at a health care
		G0270-G0271	Medical nutrition therapy	8/1/2011)	facility
		S9449	Weight management classes, nonphysician provider; per session	V77.8	Special screening for endocrine, nutritional,
		S9452	Nutrition classes, nonphysician provider; per session		metabolic, and immunity disorders; obesity
					alsolacis, obesity

Osteoporosis screening	, ,	76977	Ultrasound bone density measurement and interpretation, peripheral site(s), any method	V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy
	risk for osteopo- rotic fractures	77078	Computed tomography, bone mineral density study, one or more sites; axial skeleton (e.g., hips, pelvis, spine)	V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy
	and All women age 65* and older	77079	Computed tomography, bone mineral density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)	V49.81	(Effective 1/1/2013) - Other conditions influencing health status; asymptomatic post-
	*Effective 01/01/13, all	77080	Dual-energy X-ray absorptiometry (DXA), bone density study, one or more sites; axial skeleton (e.g., hips, pelvis, spine)		menopausal status (age- related)
	women, regardless of age.	77081	Dual-energy X-ray absorptiometry (DXA), bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)	V70.0 (Effective 8/1/2011)	Routine general medical examination at a health care facility
		77082	Dual-energy X-ray absorptiometry (DXA), bone density study, one or more sites; vertebral fracture assessment	V82.81	Special screening for other conditions; osteoporosis
		77083	Radiographic absorptiometry (e.g., photodensitometry, radiogrammetry), 1 or more sites		
		78350	(Effective 1/1/2013) - Bone density (bone mineral content) study, one or more sites, single photon absorptiometry		
		99385-99387	(Allowed for women of ANY age effective 1/1/2013)  — Initial preventive visit - ages 18+ years		
		99395-99397	(Allowed for women of ANY age effective 1/1/2013)  — Periodic preventive visit - ages 18+ year		
		99201-99215	Office visits		
		99386 — 99387	Initial preventive visit — ages 40+ years		
		99396 — 99397	Periodic preventive visit — ages 40+ years		
		99401-99404	Preventive medicine counseling		
		G0130	(Effective 1/1/2013) — Single energy X-ray absorptiometry (SEXA) bone density study, one or more sites; appendicular skeleton (peripheral)		

Behavioral	Adults at high risk	96150-96151	Health and behavior assessment	V15.7	Other personal history presenting
counseling to	Addits at High risk	96152-96154	Health and behavior intervention	V13.7	hazards to health; contraception
prevent sexually		99201-99215	Office visits	-	,,
transmitted				V22.0 - V22.2	(Effective 9/1/2013) —
infections (STIs)		99383-99387	Initial preventive visit — ages 5-65+ years	_	Normal pregnancy
		99393-99397	Periodic preventive visit — ages 5-65+ years	V23.0 - V23.9	(Effective 9/1/2013) —
		99401-99404	Preventive medicine counseling	V23.0 V23.7	High-risk pregnancy
				V25.01-V25.49	Encounter for contraceptive management (female only)
		\	V65.45	Other persons seeking consultation; counseling on	
		G0445	High intensity behavioral counseling to prevent sexually transmitted infection, performed semi-annually, 30 minutes		other sexually transmitted diseases
		S9445-S9446	Continued patient education, not otherwise classified, nonphysician provider	V69.2	Problems related to lifestyle; high-risk sexual behavior
				V70.0 (Effective 8/1/2011)	General routine exam
				V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear
Tobacco use	All adults	99201-99215	Office visits	V15.82	Personal history of tobacco
counseling and		99385-99387	Initial preventive visit — ages 18-65+ years		use
cessation interventions		99395-99397	Periodic preventive visit — ages 18-65+ years	V22.0 - V22.2	(Effective 9/1/2013) —
interventions		99401-99404	Preventive medicine counseling	VZZ.0 VZZ.Z	Normal pregnancy
		99406-99407	Smoking and tobacco use cessation counseling visit	V23.0 - V23.9	
		G0436-G0437	Smoking & tobacco cessation counseling visit		(Effective 9/1/2013) —
		S4990-S4991	Nicotine patches		High-risk pregnancy
		S4995	Smoking cessation gum	V70.0	Routine general medical exams
		S9075	Smoking cessation treatment	(Effective	
		S9445-S9446	Patient education, not otherwise classified, non- physician provider	8/1/2011)	Tobacco use disorder
		S9453	Smoking cessation classes, nonphysician provider	303.1	iobacco use disorder
				649.0	Tobacco use disorder complicating pregnancy

Syphilis	All adults at	86592-86593	Syphilis test, non-treponemal antibody	V70.0	Routine general medical
screening	increased risk for	86780	Antibody; treponema pallidum	(Effective	examination at a health care
	syphilis infection	99201-99215	Office visits	8/1/2011)	facility
		99385-99387	Initial preventive visit — ages 18-65+ years	V72.31	Gynecological exam with or
		99395-99397	Periodic preventive visit — ages 18-65+ years	(Effective	without pap smear
		99401-99404	Preventive medicine counseling	2/1/2014)	
				V74.5	Special screening exam for bacterial and spirochetal diseases; venereal disease
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
Prevention	Adults age 65 years	97001-97002	Physical therapy evaluation	Any Diagnosis for adults age 65 and older.	
of Falls	or older who are at increased risk for falls	97012-97039	Physical therapy modalities		
(Effective 5/1/2013 for new business		97110	Therapeutic procedure, one or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility		
reform policies with policy effective date of 5/1/2013 or later. Effective		97112	Therapeutic procedure, one or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities		
1/1/2014 for all other reform policies with a		97113	Therapeutic procedure, one or more areas, each 15 minutes; aquatic therapy with therapeutic exercises		
policy effective date prior to 5/1/2013.)		97116	Therapeutic procedure, one or more areas, each 15 minutes; gait training (includes stair climbing)		
,		97150	Therapeutic procedure(s), group		
		97530	Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes		

Vitamin D supplementation  (Effective 5/1/2013 for new business reform policies with policy effective date of 5/1/2013 or later. Effective 1/1/2014 for all other reform policies with a policy effective date prior to 5/1/2013.)	Adults age 65 or older only	age 65-70: allow	ated with this recommendation — Over-the-counter V wable up to 800IU over the age of 70. Will also allow e approved recommendation of 600IU or 800IU of Vita	calcium & Vitam	in D combination supplements
Skin Cancer  (Effective 5/1/2013 for new business reform policies with policy effective date of 5/1/2013 or later. Effective 1/1/2014 for all other reform policies with a policy effective date prior to 5/1/2013.)	All Young Adults ages 10-24 years	99201-99215	Office visits	V76.43	Special screening examination for malignant neoplasms of the skin

# Guide to Covered Preventive Services Pregnant Women



Service	Patient	Procedure Code	Procedure Description	Related Diagnosis Code(s)	Diagnosis Code Description
Alcohol misuse screening and	All pregnant women	90801-90815	Psychotherapy interviews/visits — outpatient	305.00-305.03	Alcohol abuse
counseling		99201-99215	Office visits	655.40-655.43	Known or suspected fetal
		99401-99404	Preventive medicine counseling		abnormality affecting management of mother;
		H0001	Alcohol and/or drug assessment		suspected damage to fetus
		H0005	Alcohol and/or drug services; group counseling	-	from other disease in mother (includes alcohol addiction)
		H0006	Alcohol and/or drug services; case management	760.71 V70.0 (Effective	Noxious influences affecting fetus or newborn via placenta or breast milk; alcohol  Routine general medical exam
		H0015	Alcohol and/or drug services; intensive outpatient, including assessment, counseling; crisis intervention, and activity therapies or education		
		H0049	Alcohol and/or drug screening	8/1/2011)	
		H0050	Alcohol and/or drug services, brief intervention, per 15 minutes	V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy  (Effective 9/1/2013) — High-risk pregnancy
		T1006, T1007	Alcohol and/or substance abuse services	V23.0 - V23.9	
		T1012	Alcohol and/or substance abuse services	VZ3.U - VZ3.9	

Anemia	All pregnant	83540	Iron chemistry	V22.0-V22.2	Normal pregnancy
screening	women	82728	(Effective 1/1/2013) — Ferritin chemistry		
		84466	(Effective 1/1/2013) — Transferrin chemistry	V23.0-V23.9	High-risk pregnancy
		85025	(Effective 1/1/2013) — Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	V70.0 (Effective 8/1/2011)	Routine general medical exam
		85027	(Effective 1/1/2013) — Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count)	V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear
		85041	(Effective 1/1/2013) — Blood count; red blood cell (RBC), automated	V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
				V78.0	Preventive medicine counseling
Bacteriuria	All pregnant	87086-87088	Culture, bacterial, urine	V22.0-V22.2	Normal pregnancy
screening	women			V23.0-V23.9	High-risk pregnancy
				V70.0 (Effective 8/1/2011)	Routine general medical exam
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
				V81.5	Screening for asymptomatic bacteriuria
				640.00 - 659.73	Complications related to pregnancy
Breastfeeding counseling	All pregnant wom- en and women	99078	Physician educational services rendered to patients in group setting	V24.1	Lactating mother (supervision of lactation)
	with newborns	99201-99215	Office visits	\	De tier were bestimt en en
		99401-99404	Preventive medicine counseling	V70.0 (Effective	Routine general medical exam
		S9443	Lactation classes, nonphysician provider	8/1/2011)	
				V22.0 - V22.2 V23.0 - V23.9	(Effective 9/1/2013) — Normal pregnancy
				123.0 Y23.9	(Effective 9/1/2013) — High-risk pregnancy

Cervical	All pregnant	*ONLY covered if billed	d without visit $-$ if office visit is billed, then th	is code is inclus	ive to the visit.
cancer screening	women	87620-87622	(Effective 8/1/2012 for reform policies with policy effective dates of 8/1/2012 - 12/31/2012. Effective 1/1/2013 for all other reform policies) Infectious agent detection by nucleic acid; human papillomavirus	V22.0-V22.2 (Effective 7/2/2012) V23.0-V23.9 (Effective	Normal pregnancy High-risk pregnancy
		88141-88155	Cytopathology, cervical or vaginal	7/2/2012)	
		88164-88167	Cytopathology, slides, cervical or vaginal	V72.31	Gynecological exam with or
		88174, 88175	Cytopathology, cervical or vaginal		without pap smear
		G0101*	Cervical or vaginal cancer screening; pelvic and clinical breast exam	V76.2	Special screening for malignant
		G0123, G0124	Screening cytopathology, cervical or vaginal		neoplasm; cervix
		G0141-G0148	Screening cytopathology smears, cervical or vaginal	V72.62 (Effective	Laboratory examination ordered as part of a routine general
		P3000, P3001	Screening Pap smear, cervical or vaginal	5/1/2012)	medical examination
		Q0091*	Screening Pap smear, obtaining, preparing and conveyance to lab	V70.0 (Effective 8/1/2011)	Routine general medical exam
		S0610*	Annual gynecological exam, new patient		
		S0612*	Annual gynecological exam, established patient	V73.81	(Effective 8/1/2012 for reform policies with policy effective dates of 8/1/2012 - 12/31/2012. Effective 1/1/2013 for all other reform policies) Special screening exam for viral & chlamydial diseases; HPV
				V73.89	(Effective 8/1/2012 for reform policies with policy effective dates of 8/1/2012 - 12/31/2012. Effective 1/1/2013 for all other reform policies) Special screening exam for viral & chlamydial diseases; other specified

Chlamydia	All pregnant	86631, 86632	Antibody immunoassay; chlamydia	V22.0-V22.2	Normal pregnancy
	women age 24 and	87110	Culture, chlamydia, any source	(Effective	
screening	younger and for older pregnant women who are at	87270	Infectious agent detection by immunofluo- rescent technique; chlamydia trachomatis	7/2/2012) - V23.0-V23.9	High-risk pregnancy
	increased risk	87320	Infectious agent antigen detection by enzyme immunoassay technique; chlamydia trachomatis	(Effective 7/2/2012)	The first pregnancy
		87490-87492	Infectious agent antigen detection by nucleic acid (DNA or RNA); chlamydia trachomatis	V70.0 (Effective 8/1/2011)	Routine general medical exam
		87810	Infectious agent antigen detection by immunoassay with direct optical observation; chlamydia trachomatis	V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
				V73.88	Special screening exam for other specified chlamydial diseases
				V73.98	Special screening exam for unspecified chlamydial diseases
Screening for	All pregnant	82947	Glucose; quantitative, blood	630-679.14	Complications of pregnancy
gestational	women	82948	Glucose; blood, reagent strip	V22 0 V22 2	Name of a second of
diabetes		82950	Glucose; post glucose dose	V22.0-V22.2	Normal pregnancy
(Effective		82951	Glucose; tolerance test, 3 specimens	V23.0-V23.9	High-risk pregnancy
08/01/2012 for new		82952	Glucose; tolerance test, each additional specimen		
business reform policies with policy effective date of 8/1/2012 or later. Effective 01/01/2013 for all reform policies.)		83036	Hemoglobin; glycosylated (A1C)		

Gonorrhea screening	, ,	87070	Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates	V22.0-V22.2 (Effective 7/2/2012)	Normal pregnancy
		87590	Neisseria gonorrhoeae, direct probe technique	V23.0-V23.9	High-risk pregnancy
			Neisseria gonorrhoeae, amplified probe technique	(Effective 7/2/2012)	
		87592	Neisseria gonorrhoeae, quantification	V70.0	Routine general medical
		87850	(Effective 1/1/2014) — Neisseria gonorrhoeae, Infectious agent detection by immunoassay with direct optical	(Effective 8/1/2011)	examination at a health care facility
		87081	observation  Culture, presumptive, pathogenic organisms, screening	V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
				V74.5	Special screening exam for bacterial & spirochetal diseases; venereal disease
Hepatitis B screening	All pregnant women	87340	Infectious agent antigen detection by enzyme immunoassay technique; hepatitis B surface antigen (ABsAg)	V22.0-V22.2 V23.0-V23.9	Normal pregnancy High-risk pregnancy
		87341	Infectious agent antigen detection by	VZ3.0-VZ3.9	Trigit-risk pregnancy
		0/341	enzyme immunoassay technique; hepatitis B surface antigen (ABsAg) neutralization	V02.61	Carrier or suspected carrier of infectious disease; hepatitis B carrier
				V70.8-V70.9	Other & Unspecified general medical examination
				V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
				V70.0	Routine general medical exam

Rh (D) Incompatibility	All pregnant women	86850	Antibody screen, RBC, each serum technique	V22.0-V22.2	Normal pregnancy
screening		86870	Antibody identification, RBC antibodies, each panel for each serum technique	V23.0-V23.9	High-risk pregnancy
		86886	Antihuman globulin test (Coombs test); indirect, each antibody titer	656.1	Other known or suspected fetal and placental problems affecting management of mother; Rhesus
		86901	Blood typing; Rh (D)		isoimmunization; unspecified
		90384-90386	Rho(D) immune globulin, human		, ,
		J2788-J2792	Injection, Rho D immune globulin	656.11	Other known or suspected fetal and placental problems affecting management of mother; Rhesus isoimmunization; delivered, with or without mention of antepar- tum condition
				656.13	Other known or suspected fetal and placental problems affecting management of mother; Rhesus isoimmunization; antepartum condition or complication
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
				V70.0 (Effective 8/1/2011)	Routine general medical exam
				V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear

Syphilis	All pregnant	86592, 86593	Syphilis test, non-treponemal antibody	V22.0-V22.2	Normal pregnancy
screening	women	86780	Antibody; treponema pallidum	V23.0-V23.9	High-risk pregnancy
				V70.0 (Effective 8/1/2011)	Routine general medical examination at a health care facility
				V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
				V74.5	Special screening exam for bacterial & spirochetal diseases; venereal disease
Tobacco use	All pregnant	99201-99215	Office visits	V15.82	Personal history of tobacco use
counseling and cessation	women	99383, 99384	Initial preventive visit — ages 5-17 years	V70.0 (Effective	Routine general medical exam
interventions		99393, 99394	Periodic preventive visit — ages 5-17 years		
		99385-99387	Initial preventive visit — ages 18-65+ years	8/1/2011)	
		99395-99397	Periodic preventive visit — ages 18-65+ years	305.1	Tobacco use disorder
		99401-99404	Preventive medicine counseling	649.0	Tobacco use disorder
		99406, 99407	Smoking and tobacco use cessation counseling visit	047.0	complicating pregnancy
		G0436-G0437	Smoking & tobacco cessation counseling visit	V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy
		S4990, S4991	Nicotine patches	\(\(\alpha\)	(F(C ): 0 (4 (2042)
		S4995	Smoking cessation gum	V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy
		S9075	Smoking cessation treatment		riigii risik pregnancy
		S9445, S9446	Patient education, not otherwise classified, nonphysician provider		
		S9453	Smoking cessation classes, nonphysician provider		

Prenatal office visits	All pregnant women	99201-99215	Office visits	630-679.14	Complications of pregnancy
(Effective 08/01/2012				V22.0-V22.2	Normal pregnancy
for new business				V23.0-V23.9	High-risk pregnancy
reform					
policies with policy					
effective date of 8/1/2012					
or later.					
Effective 01/01/2013					
for all reform					
policies.)	All promont	*ONLY and of and a FO4	25 F0/2/ can be billed now magnetic. They can	ah inaluda multi	ala visita. If weaviday billa glabal
Antepartum care	All pregnant women		25-59426 can be billed per pregnancy. They ea hese are included in that charge and would ne		
(Effective		59425*	Antepartum care visits — 4-6 visits	630-679.14	Complications of pregnancy
08/01/2012		59426*	Antepartum care visits $-7$ or more visits	V22.0-V22.2	Normal pregnancy
for new business		59400	Routine obstetric care including antepartum care, vaginal delivery, and postpartum care		,
reform			(only the antepartum care portion of the	V23.0-V23.9	High-risk pregnancy
policies with policy		50540	global charge is covered under Reform)		
effective date		59510	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care		
of 8/1/2012 or later.			(only the antepartum care portion of the		
Effective		59610	global charge is covered under Reform)  Routine obstetric care including antepartum		
01/01/2013 for all reform		37010	care, vaginal delivery, and postpartum care,		
policies.)			after previous cesarean delivery (only the antepartum care portion of the global		
			charge is covered under Reform)		
		59618	Routine obstetric care including antepartum care, cesarean delivery, and postpartum		
			care, following attempted vaginal delivery		
			after previous cesarean delivery (only the		
			antepartum care portion of the global charge is covered under Reform)		
		80055	(Effective 3/5/2014) obstetric panel		

## Guide to Covered Preventive Services Child Immunizations



Service	Patient Age	Procedure Code	Procedure Description		
Administration	Covered through Age 8	90465	Immunization administration, younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), physician counsels family/patient first; first injection, per day		
		90466	Immunization administration, younger than 8 years of age (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), physician counsels family/patient first; each additional injection, per day		
		90467	Immunization administration, younger than 8 years of age (includes intranasal or oral routes of administration), physician counsels family/patient first; first injection, per day		
		90468	Immunization administration, younger than 8 years of age (includes intranasal or oral routes of administration), physician counsels family/patient first; each additional injection, per day		
	All children	90460 (Effective 1/1/2011)	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first vaccine/toxoid component.		
		90461 (Effective 1/1/2011)	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine/toxoid component.		
		90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); one vaccine		
		90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine		
		90473	Immunization administration by intranasal or oral route; one vaccine		
		90474	Immunization administration by intranasal or oral route; each additional vaccine		

Diptheria, Tetanus, Pertussis	Age 4 years through 6 years	90696	Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated (DTaP-IPV), when administered to children 4-6 years of age, for intramuscular use
	Age 6 weeks through 18 years	90698	Diphtheria, tetanus, acellular pertussis, Haemophilus B and polio (DTaP-Hib-IPV)
	Age 6 weeks through 6 years	90700	Diphtheria, tetanus and acellular pertussis vaccine (DtaP), when administered to individuals younger than 7 years, for intramuscular use
	Age 6 weeks and older	90701	Diphtheria, tetanus and whole cellular pertussis vaccine (DTP), for intramuscular use
	Age 6 weeks through 6 years	90702	Diphtheria and tetanus toxoids (DT) adborbed when administered to individuals younger than 7 years, for intramuscular use
	Age 6 weeks and older	90703	Tetanus toxoid adsorbed, for intramuscular use
	Age 7 years and older	90714	Tetanus and diphtheria (Td) adsorbed, preservative free, when administered to individuals 7 years or older, for intramuscular use
		90715	Tetanus, diphtheria and acellular pertussis vaccine(Tdap), when administered to individuals 7 years or older, for intramuscular use
	Age 12 months and older	90718	Tetanus and diphtheria toxoids (Td) adsorbed when administered to individuals 7 years or older, for intramuscular use.
	Age 6 weeks and older	90719	Diphtheria toxoid, for intramuscular use
	Age 6 weeks through 17 months	90720	Diptheria, tetanus toxoids, and whole cell pertussus vaccine and Hemophilus influenza B vaccine (DTP-Hib), for intramuscular use
		90721	Diptheria, tetanus toxoids, and acellular pertussus vaccine and Hemophilus influenza B vaccine (DTaP-Hib), for intramuscular use
	Age 6 weeks through 18 months	90723	Diptheria, tetanus toxoids, and acellular pertussus vaccine, Hepatitis B, and poliovirus vaccine, inactivated (DTaP-HepB-IPV), for intramuscular use
Haemophilus	Age 6 weeks through 17 months	90645	Haemophilus influenza b vaccine, HbOC4-dose schedule
influenza type B		90646	Haemophilus influenza b vaccine, PRP-D booster only
		90647	Haemophilus influenza b vaccine, PRP-OMP 3-dose schedule
		90648	Haemophilus influenza b vaccine, PRP-T 4-dose schedule
	Age 6 weeks through 18 years	90698	Diphtheria, tetanus, acellular pertussis, Haemophilus B and polio (DTaP-Hib-IPV)
	Age 6 weeks through 17 months	90720	Diptheria, tetanus toxoids, and whole cell pertussus vaccine and Hemophilus influenza B vaccine (DTP-Hib), for intramuscular use
		90721	Diptheria, tetanus toxoids, and acellular pertussus vaccine and Hemophilus influenza B vaccine (DTaP-Hib), for intramuscular use
Hepatitis A	Age 18 and older	90632	Hepatitis A vaccine, adult dosage, for intramuscular use
	Age 12 months through 18 years	90633	Hepatitis A vaccine, pediatric/adolescent dosage, 2-dose schedule
		90634	Hepatitis A vaccine, pediatric/adolescent, 3-dose schedule
	Age 18 and older	90636	Hepatitis A and B vaccine, adult dosage, for intramuscular use

Hepatitis B	Age 18 and older	90636	Hepatitis A and B vaccine, adult dosage, for intramuscular use
	Age 6 weeks through 18 months	90723	Diptheria, tetanus toxoids, and acellular pertussus vaccine, Hepatitis B, and poliovirus vaccine, inactivated (DTaP-HepB-IPV), for intramuscular use
	All patient ages	90740	Hepatitus B vaccine, dialysis or immunosuppressed patient dosage (3-dose schedule), for intramuscular use
	Covered through age 18	90743	Hepatitis B vaccine, adolescent (2-dose schedule), for intramuscular use
		90744	Hepatitis B vaccine, pediatric/adolescent dosage (3-dose schedule), for intramuscular use
	All patient ages	90746	Hepatitis B vaccine adult dosage
		90747	Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4-dose schedule), for intramuscular use
	Age 6 weeks through 17 months	90748	Hepatitis B and Hemophilus influenza b vaccine (HepB-Hib), for intramuscular use
Human Papillomavirus	Females age 9 through 26 years Males age 11 through 26 years	90649	Human papillomavirus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3-dose schedule, for intramuscular use
	(Effective 1/1/2012 for all reform plans)	90650	Human papillomavirus (HPV) vaccine, types 16, 18 (bivalent), 3-dose schedule, for intramuscular use
Inactivated Poliovirus	Age 4 years through 6 years	90696	Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated (DTaP-IPV), when administered to children 4-6 years of age, for intramuscular use
	Age 6 weeks through 18 years	90698	Diphtheria, tetanus, acellular pertussis, Haemophilus B and polio (DTaP-Hib-IPV)
		90713	Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use
	Age 6 weeks through 18 months	90723	Diptheria, tetanus toxoids, and acellular pertussus vaccine, Hepatitis B, and poliovirus vaccine, inactivated (DTaP-HepB-IPV), for intramuscular use

Influenza	All ages	90654	Influenza virus vaccine, split virus, preservative free, for intradermal use
	Age 6 months through 35 months	90655	Influenza virus vaccine, split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use
	Age 3 and older	90656	Influenza virus vaccine, split virus, preservative free, when administered to individuals 3 years and older, for intramuscular use
	Age 6 months through 35 months	90657	Influenza virus vaccine, split virus, when administered to children 6-35 months of age, for intramuscular use
	Age 3 and older	90658	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use
	Age 6 months and older	90660	Influenza virus vaccine, live, for intranasal use
	All ages	90661	(Effective 11/20/2012) — Influenza virus vaccine, derived from cell cultures, subunit, preservative and antibiotic free, for intramuscular use
	Age 6 months and older	90672	(Effective 1/1/2013) — Influenza virus vaccine, quadrivalent, live, for intranasal use
	Age 18 and older	90673	(Effective 1/1/2014) — Influenza virus vaccine, trivalent, derived from recombinant DNA (RIV3), hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
	Age 6 months through 35 months	90685	(Effective 6/7/2013) — Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use
	Age 6 months and older	90686	(Effective 1/1/2013) — Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to individuals 3 years of age and older, for intramuscular use
	Age 3 and older	90688	(Effective 8/16/2013) — Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use
	Age 6 months and older	Q2034	(Effective 7/1/2012) — Influenza virus vaccine, split virus, for intramuscular use (Agriflu) Sipuleucel-t, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion
		Q2035	(Effective 7/1/2012) — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Afluria)
		Q2036	(Effective 7/1/2012) — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Flulaval)
		Q2037	(Effective 7/1/2012) — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluvirin)
		Q2038	(Effective 7/1/2012) — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone)
		Q2039	(Effective 7/1/2012) — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (not otherwise specified)

Measles, Mumps	Age 12 months and older	90704	Mumps virus vaccine, live, for subcutaneous use
and Rubella		90705	Measles virus vaccine, live, for subcutaneous use
		90706	Rubella virus vaccine, live, for subcutaneous use
		90707	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use
		90708	Measles and rubella virus vaccine (MMR), live, for subcutaneous use
		90710	Measles, Mumps and Rubella and Varicella (MMRV), live, for subcutaneous use
Meningococcal	Age 2 years and older	90733	Meningococcal polysaccharide vaccine, (any group(s)), for subcutaneous use
(meningitis)		90734	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetravalent), for intramuscular use
	Age 2 months through 15 months.	90644	(Effective 1/1/2013) — Meningococcal conjugate vaccine, serogroups C & Y and Hemophilus influenza B vaccine (Hib-MenCY), 4 dose schedule, when administered to children 2-15 months of age, for intramuscular use
Pneumococcal	Age 6 weeks and older	90669	Pneumococcal conjugate vaccine, 7 valent, for intramuscular use
(pneumonia)		90670	Pneumococcal conjugate vaccine, 13 valent, for intramuscular use
	Age 2 years and older	90732	Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use
Rotavirus	Age 6 weeks through 7 months	90680	Rotavirus vaccine, pentavalent, 3-dose schedule, live, for oral use
		90681	Rotavirus vaccine, human, attenuated, 2-dose schedule, live, for oral use
Varicella	Age 12 months and older	90710	Measles, Mumps and Rubella and Varicella (MMRV), live, for subcutaneous use
(chicken pox)		90716	Varicella virus vaccine, live, for subcutaneous use

## Guide to Covered Preventive Services Children and Adolescents



Service	Patient	Procedure Cod	es	DX Codes	
Well-child preventive visits	Covered through age 21	99381-99385	Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient	V20.0-V20.32, V21.0-V21.9, V30.00-V39.2, V70.0, V70.3, V70.5, V70.8-V70.9,	Well child — Routine visits
	Covered through age 21	99391-99395	Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient	V72.31, V76.2	
Oral fluoride supplementation	Age 6 months through 5 years — when primary water source is deficient in fluoride	D1206	Topical fluoride varnish	n/a	No specific diagnosis code requirements are associated with this recommendation

•	Adolescents at high risk	86689	Antibody; HTLV or HIV antibody, confirmatory test (e.g., Western Blot)	V69.2	Problems related to lifestyle; high-risk
		86701-86703	Antibody; HIV-1 and/or HIV-2	_	sexual behavior
		87390	Infectious agent antigen detection by enzyme immunoassay technique; HIV-1	V69.8-V69.9	Problems related to lifestyle; other and
		87391	Infectious agent antigen detection by enzyme immunoassay technique; HIV-2		unspecified problems related to lifestyle
		99201-99215	Office visits		
		99383-99387	Initial preventive visit — ages 5-65+ years	V70.0	Routine general medica examination at a health
		99393-99397	Periodic preventive visit — ages 5-65+ years	(Effective 8/1/2011)	care facility
		99401-99404	Preventive medicine counseling	]	
		G0432	Infectious agent antibody detection by enzyme immunoassay technique, HIV-1 and/or HIV-2, screening	V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear
		G0433	Infectious agent antibody detection by enzyme- linked immunoabsorbent assay technique, HIV-1 and/or HIV-2, screening	V73.89	Special screening exam for viral and chlamydial diseases; other specified viral diseases
		G0435	Infectious agent antibody detection by rapid antibody test, HIV-1 and/or HIV-2, screening		
		S3645	HIV-1 antibody testing of oral mucosal transudate	V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
				V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy
				V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy

Major depressive disorder screening		Benefits are for the screening of MDD, but not for the treatment itself. Please refer to your policy to determine coverage for the treatment of Major Depressive Disorder.					
	Age 12 through 18	90801-90802	Psychiatric diagnostic interview examination	V79.0	Special screening		
	years	90785	(Effective 1/1/2013) — Interactive complexity (list separately in addition to the code for primary procedure)		for mental disorders and developmental handicaps; depression Routine general medical exam		
		90791-90792	(Effective 1/1/2013) — Psychiatric diagnostic evaluation	V70.0 (Effective			
		96101-96103	Psychological testing	8/1/2011)	CAUTT		
		96116	Neurobehavioral status exam				
		96118-96120	Neuropsychological testing				
		96150-96151	Health and behavior assessment				
		G0444	Annual depression screening, 15 minutes				
		H0002	Behavioral health screening to determine eligibility for admission to treatment program				
		H0031	Mental health assessment, by nonphysician				
Iron supplementation	Age 6 months to 12 months at increased risk for iron deficiency anemia	No codes assoc	iated with this recommendation — Over-the-counter	iron supplements			

Behavioral	Adolescents at high	96150-96151	Health and behavior assessment	V15.7	Other personal history
counseling to	risk	96152-96154	health and behavior intervention		presenting hazards to
prevent sexually transmitted		99201-99215	Office visits		health; Contraception
infections (STIs)		99383-99387	Initial preventive visit — ages 5-65+ years	V25.01-V25.49	Encounter for contraceptive
		99393-99397	Periodic preventive visit — ages 5-65+ years		
		99401-99404	Preventive medicine counseling		management
		S9445-S9446		V65.45	Other persons seeking consultation; Counseling on other sexually transmitted diseases
				V69.2	Problems related to lifestyle; High-risk sexual behavior
			Patient education, not otherwise classified, nonphysician provider		
			nonpriyoreian provider	V70.0 (Effective 8/1/2011)	Routine general medical exam
				V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear
				V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy
				V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy

<sup>\*</sup>ONLY covered if billed without visit - if office visit is billed, then this code is inclusive to the visit.

Syphilis screening	Adolescents at	86592-86593	Syphilis test, non-treponemal antibody	V70.0	Routine general medical
	increased risk	86780	Antibody; treponema pallidum	(Effective	examination at a health
		99201-99215	Office visits	8/1/2011)	care facility
		99383-99387	Initial preventive visit — ages 5-65+ years	V72.31	Gynecological exam
		99393-99397	Periodic preventive visit — ages 5-65+ years	(Effective	with or without pap
		99401-99404	Preventive medicine counseling	2/1/2014)	smear
				V74.5	Special screening exam for bacterial and spirochetal diseases; venereal disease
				V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
Visual impairment	Covered through	99172	Visual function screening	V80.2	Special screening for
screening	age 5	99173	Screening test of visual acuity		neurological, eye, and
		99174	Ocular photoscreening		ear diseases; other eye conditions
		92002-92014	Ophthalmological services; medical exam and evaluation	V70.0 (Effective	Routine general medical
		99201-99215	Office visits		exam
		99381-99382	Initial preventive visit — infant to 4 years	8/1/2011)	
		99391-99392	Periodic preventive visit — infant to 4 years		
		99401-99404	Preventive medicine counseling		

Cervical cancer screening via Pap test	Sexually active women with cervix	policy effective Effective 1/1/20 Infectious agent papillomavirus	(Effective 8/1/2012 for reform policies with policy effective dates of 8/1/2012 - 12/31/2012. Effective 1/1/2013 for all other reform policies) Infectious agent detection by nucleic acid; human papillomavirus	V72.31 V73.81	Gynecological exam with or without Pap smear  (Effective 8/1/2012 for reform policies with policy effective dates of 8/1/2012 - 12/31/2012. Effective 1/1/2013 for all other reform policies)
		88141-88155	Cytopathology, cervical or vaginal	-	
		88164-88167	Cytopathology, slides, cervical or vaginal		
		88174, 88175	Cytopathology, cervical or vaginal		
		99201-99215	Office visits		Special screening exam
		99383-99387	Initial preventive visit — ages 5-65+ years		for viral & chlamydial
		99393-99397	Periodic preventive visit — ages 5-65+ years		diseases; HPV
		99401-99404	Preventive medicine counseling	for re policy of 8/1 12/31 01/01	(Effective 08/01/2012 for reform policies with policy effective dates of 8/1/2012 or later 12/31/2012. Effective
		G0101*	Cervical or vaginal cancer screening; pelvic and clinical breast exam		
		G0123, G0124	Screening cytopathology, cervical or vaginal		
		G0141-G0148	Screening cytopathology smears, cervical or vaginal		01/01/2013 for all other reform policies.)
				V76.2	Special screening for
		P3000, P3001	Screening Pap smear, cervical or vaginal	-	malignant neoplasm;
		Q0091*	Screening Pap smear, obtaining, preparing and conveyance to lab.	V70.0	cervix Routine general medical
		S0610*	Annual gynecological exam, new patient	(Effective 8/1/2011)	examination at a health care facility
		S0612*	Annual gynecological exam, established patient	V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination

Chlamydia infection	All women age 24	86631-86632	Antibody immunoassay; chlamydia	V73.88	Special screening exam
screening	and younger who are sexually active or Women age	87110	Culture, chlamydia, any source		for other specified
		87270	Infectious agent detection by immunofluorescent technique; chlamydia trachomatis	V73.98	chlamydial diseases  Special screening
	24+ who are at increased risk	87320	Infectious agent antigen detection by enzyme immunoassay technique; chlamydia trachomatis	773.70	exam for unspecified chlamydial diseases
		87490-87492	Infectious agent antigen detection by nucleic acid (DNA or RNA); chlamydia trachomatis	V70.0 (Effective	Routine general medical examination at a health care facility  Gynecological exam with or without pap smear
		87810	Infectious agent antigen detection by immunoassay with direct optical observation; chlamydia trachomatis	8/1/2011)	
		99201-99215	Office visits	V72.31 (Effective	
		99383-99387	Initial preventive visit — ages 5-65+ years	2/1/2014)	
		99393-99397	Periodic preventive visit — ages 5-65+ years	V72 (2	Laboratory examination ordered as part of a routine general medical examination
		99401-99404	Preventive medicine counseling	V72.62 (Effective 5/1/2012)	
		99411-99412	Preventive medicine counseling, group		
		G0447	Face-to-face behavioral counseling for obesity, 15 minutes.		
		G0270-G0271	Medical nutrition therapy		
Gonorrhea screening	All sexually active women who are at risk	87070	Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates	V74.5	Special screening exam for bacterial and spirochetal diseases;
		87081	Culture, presumptive, pathogenic organisms, screening		venereal disease
		87590	Neisseria gonorrhoeae, direct probe technique	V70.0 (Effective	Routine general medical examination at a health
		87591	Neisseria gonorrhoeae, amplified probe technique	8/1/2011)	care facility
		87592	Neisseria gonorrhoeae, quantification	\/70 24	
		87850	(Effective 1/1/2014) — Neisseria gonorrhoeae, Infectious agent detection by immunoassay with direct optical observation	V72.31 (Effective 2/1/2014)	Gynecological exam with or without pap smear
		99201-99215	Office visits	V72.62	Laboratory examination
		99383-99387	Initial preventive visit — ages 5-65+ years	(Effective	ordered as part of a
		99393-99397	Periodic preventive visit — ages 5-65+ years	5/1/2012)	routine general medical
		99401-99404	Preventive medicine counseling		examination

Hepatitis C screening (Effective		ng one-time scre	for hepatitis C virus (HCV) infection in persons at hig ening for HCV infection to adults born between 1945 ages.		
6/25/2014 for new	All ages	86803	Hepatitis C antibody	042	Human immunodeficiency
business reform policies with an		86804	Hepatitis C antibody; confirmatory test		virus (HIV) disease
effective date of 6/25/2014 or later.		87520	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique	079.52	Human immunodeficiency virus, type II (HIV-2)
Effective 1/1/2015 for all reform policies.)		87521	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed	286.0-286.9	Coagulation defects
		87522	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed	304.00-305.93	Drug dependence and non- dependent use of drugs
		87902 Infectious agent genotype analysis by nucl (DNA or RNA); Hepatitis C virus	Infectious agent genotype analysis by nucleic acid	790.4	Nonspecific elevation of levels of transaminase or lactic acid dehydro- genase (LDH) (ALT)
				V01.7	Contact with or exposure to communicable diseases other viral diseases
				V02.60	Carrier or suspected carrier of infectious diseases; viral hepatitis carrier, unspecified
				V02.62	Carrier or suspected carrier of infectious diseases; Hepatitis C carrier
				V42.0-V42.9	Organ or tissue replaced by transplant
					V45.11
				1/50.0	DI II C : 'II I

Hepatitis C screening, cont.				V69.2	Problems related to lifestyle; high-risk sexual behavior
				V70.0	Routine general medical examination at a health care facility (This DX billed with one of above CPT codes is allowable ONCE per lifetime.)
				V72.62	Laboratory examination ordered as part of a routine general medical examination (This DX billed with one of above CPT codes is allowable ONCE per lifetime.)
				584.5-586	Renal failure
Obesity	Ages 6 and older	97802-97804	Medical nutrition therapy	278.00	Obesity, unspecified
screening, counseling and behavioral		99078	Physician educational services rendered to patients in group setting	278.01	Morbid obesity
interventions		99201-99215	Office visits	V20.2	Routine infant or child
(Effective		99383, 99384	Initial preventive visit — ages 6-17 years		health check
1/1/2012)		99393, 99394	Periodic preventive visit — ages 6-17 years	\.\.70_0	D (1)
		99401-99404	Preventive medicine counseling	V70.0	Routine general medical examination at a health
		99411-99412	Preventive medicine counseling, group		care facility
		G0447	Face-to-face behavioral counseling for obesity, 15 minutes.	V77.8	Special screening for
		G0270-G0271	Medical nutrition therapy		endocrine, nutritional,
		S9449	Weight management classes, nonphysician provider; per session		metabolic, and immunity disorders; obesity
		S9452	Nutrition classes, nonphysician provider; per session	V22.0 - V22.2	(Effective 9/1/2013) —
		S9470	Nutritional counseling, dietitian visit		Normal pregnancy
				V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy

Tobacco use	All ages	99201-99215	Office visits	V15.82	Personal history of
counseling and		99383, 99384	Initial preventive visit — ages 5-17 years		tobacco use (Covered
cessation interventions		99393, 99394	Periodic preventive visit — ages 5-17 years		for all age 18+. Covered for pregnant females at
incervencions		99385- 99387	Initial preventive visit — ages 18-65+ years		any age)
		99395-99397	Periodic preventive visit — ages 18-65+ years		
		99401-99404	Preventive medicine counseling	V70.0 (Effective 8/1/2011)	Routine general medical exam
				305.1	Tobacco use disorder (Covered for all age 18+. Covered for pregnant females at any age)
		99406, 99407	Smoking and tobacco use cessation counseling visit		T. b
		S4990, S4991	Nicotine patches	649.0	Tobacco use disorder complicating pregnancy
		S4995	Smoking cessation gum		(Covered at any age)
		S9075	Smoking cessation treatment		
		S9445, S9446	Patient education, not otherwise classified, nonphysician provider	V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy
		G0436-G0437	Smoking & tobacco cessation counseling visit	VZZ.U - VZZ.Z	Normal pregnancy
		S9453	Smoking cessation classes, nonphysician provider	V23.0 - V23.9	(Effective 9/1/2013) — High-risk pregnancy

Vision screening (Effective	Covered through 21 years of age	92002-92014	Ophthalmological services; medical exam and evaluation	V20.0-V20.32	Well newborn, infant, or child
1/1/2011)		99173	Screening test of visual acuity, quantitative, bilateral	V21.0-V21.9	Child development
		99174	Ocular photoscreening with interpretation and report, bilateral	V30.00-V39.2	Newborn(s)
				V70.0	Routine general medical examination at a health care facility
				V70.3	Other general medical examination for administrative purposes
				V70.5	Health examination of defined subpopulations
				V70.8-V70.9	Other and unspecified general medical examination
				V72.0	Examination of eyes and vision
				V72.31	Gynecological exam with or without Pap smear
				V76.2	Special screening for malignant neoplasm; cervix
				V80.2	Screening for other eye conditions

Hearing screening	Covered through 21	92551	Screening test, pure tone, air only	V20.0-V20.32	Well newborn, infant,		
(Effective	years of age	92552	Pure tone audiometry (threshold); air only		or child		
1/1/2011)		92567	Tympanometry (impedance testing)	V21.0-V21.9	Child development		
		92585-92586	Auditory evoked potentials for evoked response audiometry and/or testing of central nervous system	V30.00-V39.2	Newborn(s)		
		92587-92588	Evoked otoacoustic emissions	V70.0	Routine general medical examination at a health care facility		
				V70.3	Other general medical examination for administrative purposes		
				V70.5	Health examination of defined subpopulations		
				V70.8-V70.9	Other and unspecified general medical examination		
				V72.11-V72.19	Examination of ears and hearing		
				V72.31	Gynecological exam with or without Pap smear		
							V76.2

Developmental screening/	Covered up to age 3	96110	Developmental screening; with interpretation and report, per standardized instrument form	V20.0-V20.32	Well newborn, infant, or child
autism screening/ developmental surveillance (Effective 1/1/2011)		96111	Developmental testing, (includes assessment of motor, language, social, adaptive, and/ or cognitive functioning by standarized developmental instruments) with interpretation and report	V21.0-V21.9 V30.00-V39.2	Child development  Newborn(s)
		G0451	(new for 2013) — Developmental testing, (includes assessment of motor, language, social, adaptive, and/or cognitive functioning by standarized developmental instruments) with interpretation	V70.0	Routine general medical examination at a health care facility
			and report	V70.3	Other general medical examination for administrative purposes
				V70.5	Health examination of defined subpopulations
				V70.8-V70.9	Other and unspecified general medical examination
				V79.3-V79.9	Screening for developmental handicaps in early childhood
				V72.31	Gynecological exam with or without Pap smear
				V76.2	Special screening for malignant neoplasm; cervix

,							
Psychosocial/ behavioral assessment/alcohol	Covered through 21 years of age	99401-99404	Preventive medicine counseling or risk factor reduction intervention(s)	V15.85	Personal history of contact Personal history		
		99406-99407	Smoking and tobacco use cessation counseling visit		of contact with and		
	and drug use assessment (Effective 1/1/2011)		99408-99409	Alcohol or substance (other than tobacco) abuse structured screening and brief intervention services		(suspected) exposure to potentially hazardous body fluid	
	17172011)		99411-99412	Preventive medicine counseling or risk factor reduction intervention(s) provided to individuals in a group setting	V15.89	Other specified personal history presenting hazards to health	
					V20.0-V20.32	Well newborn, infant, or child	
					V21.0-V21.9	Child development	
						V25.09	Encounter for other general counseling and advice on contraceptive management
					V30.00-V39.2	Newborn(s)	
	1				V65.3	Dietary surveillance and counseling	
	1				V65.40-V65.43	Counseling for injury prevention, substance use/abuse, exercise, NOS	
	1				V65.49	Other specified counseling	
	1				V70.0	Routine general medical examination at a health care facility	
				V70.3	Other general medical examination for administrative purposes		
					V70.5	Health examination of defined subpopulations	

Psychosocial/ behavioral assessment/alcohol and drug use assessment, cont.				V70.8-V70.9 V72.31 V76.2	Other and unspecified general medical examination  Gynecological exam with or without Pap smear
					Special screening for malignant neoplasm; cervix
Hematocrit or hemoglobin	Covered through 21 years of age	85014 85018	Blood count, hematocrit Blood count, hemoglobin	V20.0-V20.32	Well newborn, infant, or child
(Effective 1/1/2011)				V21.0-V21.9	Child development
				V30.00-V39.2	Newborn(s)
				V70.0	Routine general medical examination at a health care facility
				V70.3	Other general medical examination for administrative purposes
				V70.5	Health examination of defined subpopulations
				V70.8-V70.9	Other and unspecified general medical examination
				V72.62	Laboratory examination
					Gynecological exam with or without Pap smear
					Special screening for malignant neoplasm; cervix
				V78.0	Screening for iron deficiency anemia

Lead screening (Effective 1/1/2011)	Covered through 6 years of age	83655	Lead screening	V20.0-V20.32	Well newborn, infant, or child
17172011)				V21.0-V21.9	Child development
				V30.00-V39.2	Newborn(s)
				V70.0	Routine general medical examination at a health care facility
				V70.3	Other general medical examination for administrative purposes
				V70.5	Health examination of defined subpopulations
				V70.8-V70.9	Other and unspecified general medical examination
				V72.62	Laboratory examination
				V82.5	Screening for chemical poisoning and other contamination

Tuberculin screening (Effective 1/1/2011)	Children at higher risk for tuberculosis	86480	Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon	V01.1	Contact with or exposure to communicable diseases; tuberculosis
		86481	Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension	V03.2	Need for prophylactic vaccination and inoculation against bacterial diseases;
		86580	Skin test; tuberculosis		tuberculosis
		87116	Culture, tubercle or other acid-fast bacilli, any source, with isolation and presumptive identification of isolates	V12.01	Personal history of certain other diseases; tuberculosis
		V20.0-V20.2	(Effective 1/1/2013) — Health supervision of infant or child; routine infant (over 28 days old) or child health check	V20.0-V20.2	(Effective 1/1/2013) — Health supervision of infant or child; routine
		V74.1	(Effective 1/1/2013) — Special screening examination for bacterial and spirochetal diseases; pulmonary tuberculosis		infant (over 28 days old) or child health check
				V74.1	Special screening examination for bacterial and spirochetal diseases; pulmonary tuberculosis
				V60.0-V60.2	Housing, household, and economic circumstances
				V60.6-V60.9	Housing, household, and economic circumstances
Skin Cancer (Effective 5/1/2013 for new business reform policies with policy effective date of 5/1/2013 or later. Effective 1/1/2014 for all other reform policies with a policy effective date prior to 5/1/2013.)		99201-99215	Office visits	V76.43	Special screening examination for malignant neoplasms of the skin

Dyslipidemia	Covered through 21	80061	Lipid panel	V20.0-V20.32	Well newborn, infant,
screening (Effective	years of age	82465	Cholesterol, serum, total	-	or child
1/1/2011)		83718	Lipoprotein, direct measurement, HDL cholesterol	V21.0-V21.9	Child development
		84478	Triglycerides	V30.00-V39.2	Newborn(s)
				V70.0	Routine general medical examination at a health care facility
				V70.3	Other general medical examination for administrative purposes
				V70.5	Health examination of defined subpopulations
				V70.8-V70.9	Other and unspecified general medical examination
				V72.62	Laboratory examination
					Gynecological exam with or without Pap smear
					Special screening for malignant neoplasm; cervix
				V77.91	Special screening for endocrine, nutritional, metabolic, and immunity disorders; lipoid disorders
				V22.0 - V22.2	(Effective 9/1/2013) — Normal pregnancy
				V23.0 - V23.9	(Effective 9/1/2013) – High-risk pregnancy

## Guide to Covered Preventive Services Newborn screenings



Screening for	Screening Test	Procedure	Procedure Codes [		
Biotinidase deficiency	Spectrophotometric	81404	Molecular pathology procedure, Level 5 (e.g., analysis of 2-5 exons by DNA sequence analysis, mutation scanning or	V77.7	Screening for inborn error of metabolism
			duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder / triplet repeat by Southern blot analysis)	V77.99	Screening for other and unspecified endocrine, nutritional, metabolic, and immunity disorder
		82261	Biotinidase, each specimen		
		84311	Spectrophotometry, analyte not elsewhere specified		
Congenital adrenal hyperplasia	17-OHP immunoassay	81402	Molecular pathology procedure, Level 3 (e.g., >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis] immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants 1 exon)	v77.99 Screening for other and unspecified endocrine,	Screening for other and unspecified endocrine, nutritional, metabolic, and
		81405	Molecular pathology procedure, Level 6 (e.g., analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons)		
		82157	Androstenedione		
		82533	Cortisol; total		
		83498	Hydroxyprogesterone, 17-d		

Congenital	T4 immunoassay	84436	Thyroxine; total	V77.0	Screening for thyroid
hypothyroidism		84437	Thyroxine; requiring elution		disorders
		84439	Thyroxine; free	V30.00-V39.01	Newborn(s)
	TSH immunoassay	84443	Thyroid stimulating hormone	130.00 137.01	Trevident(s)
	Related office visits	99201-99215	Office visits	V70.0	Routine general medical
		99381	Initial preventive visit — infant	(Effective 8/1/2011)	exam
		99391	Periodic preventive visit — infant	6/1/2011)	
		99401-99404	Preventive medicine counseling	V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
Cystic fibrosis	Immunoassay and polymerase chain	83898	Molecular diagnostics; amplification, target, each nucleic acid sequence	V77.6	Screening for endocrine, nutritional, metabolic, and
	reaction; F508, panel of common	83890	Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences		immunity disorders; cystic fibrosis
	mutations	83891	Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type		
		83892	Molecular diagnostics; enzymatic digestion, each enzyme treatment		
		83896	Molecular diagnostics; nucleic acid probe, each		
		83900	Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences		
		83901	Molecular diagnostics; amplification, target, multiplex, each additional nucleic acid sequence beyond 2		
		83908	Molecular diagnostics; amplification, signal, each nucleic acid sequence		
		83909	Molecular diagnostics; separation and identification by high resolution technique, each nucleic acid preparation		
		83912	Molecular diagnostics; interpretation and report		
		83914	Mutation identification by enzymatic ligation or primer extension, single segment, each segment		

Classic galactosemia, Galactoepimerase de-	G1P uridyltransferase, G1P, and total	82775	Galactose-1-phosphate uridyl transferase; quantitative	V77.4	Screening for endocrine, metabolic, nutritional,			
fience, Galactokinase deficiency	galactose	82776	Galactose-1-phosphate uridyl transferase; screen		and immunity disorders; Galactosemia			
		84378	Sugars (mono-, di-, and oligosaccharides); single quantitative, each specimen	V82.89	Screening for other conditions; other specified conditions			
				V82.9	Screening for other conditions; unspecified conditions			
Argininemia, Argininosuccinic acid- uria, Citrullinemia, type	Amino Acids by MS/ MS	81205	BCKDHB (branced-chain keto acid dehydrogenase E1, beta polypeptide) (e.g., Maple syrup urine disease) gene analysis,	V77.7	Screening for inborn error of metabolism			
I, Citrullinemia, type II, Maple syrup urine dis-				common varients (e.g., R183P, G278S, E422X)	V77.99	Screening for other and unspecified endocrine,		
ease, Homocystinuria, Hypermethioninemia, Benign hyperphenylal- aninemia, Biopterin de- fect in cofactor biosyn- thesis, Biopterin defect				81406	Molecular pathology procedure, Level 7 (e.g., analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)		nutritional, metabolic, and immunity disorder	
in cofactor regeneration, Tyrosinemia, type I, Tyrosinemia, type II,		82127	Amino acids; single, qualitative, each specimen					
Tyrosinemia, type III					82128	Amino acids; multiple, qualitative, each specimen		
						82131	Amino acids; single, quantitative, each specimen	
		82135	Aminolevulinic acid, delta (ALA)					
			82136	Amino acids, 2 to 5 amino acids, quantitative, each specimen				
		82139	Amino acids, 6 or more amino acids, quantitative, each specimen					
		83788-83789	Mass spectrometry and tandem mass spectrometry					

Carnitine uptake defect/ carnitine transport defect, Short-chain acyl-CoA dehydrogenase deficiency, Medium/	Acylcarnitines by MS/MS	81400	Molecular pathology procedure, Level 1 (e.g., identification of single germline variant (e.g., SNP) by techniques such as restriction enzyme digestion or melt curve analysis)	V77.7 V77.99	Screening for inborn error of metabolism  Screening for other and unspecified endocrine,		
short-chain L-3 hydroxyacyl-CoA dehydrogenase deficiency, Glutaric acidemia type II, Medium-chain ketoacyl-		81401	Molecular pathology procedure, Level 2 (e.g., 2-10 SNPs, 1 methylated variant, or 1 somatic variant (typically using nonsequencing target variant analysis), or detection of a dynamic mutation disorder/triplet repeat)		nutritional, metabolic, and immunity disorder		
CoA thiolase deficiency, Medium-chain acyl		82016	Acylcarnitines; qualitative, each specimen				
mediam enam dejt		82017	Acylcarnitines; quantitative, each specimen				
		82491	Chromatography, quantitative, column; single analyte not elsewhere specified, single stationary and mobile phase				
		83788	Mass spectrometry and tandem mass spectrometry (MS, MS/MS), analyte not elsewhere specified; qualitative				
				83789	Mass spectrometry and tandem mass spectrometry (MS, MS/MS), analyte not elsewhere specified; quantitative		
		83919	Organic acids; qualitative, each specimen				
Classic phenylketonuria	Amino Acids by MS/ MS and	83788-83789	Mass spectrometry and tandem mass spectrometry	V77.3	Special screening for endocrine, nutritional,		
	Phenylalanine (PKU)	84030	Phenylalanine (PKU), blood. This code is specific to PKU only.		metabolic, and immunity disorders; phenylketonuria		
		99201-99215	Office visits. This code is specific to PKU only.	V30.00-V39.01	(PKU) Newborn(s)		
		99381	Initial preventive visit — infant. This code is specific to PKU only.	V70.0	Routine general medical		
		99391	Periodic preventive visit — infant. This code is specific to PKU only.	(Effective 8/1/2011)	exam		
		99401-99404	Preventive medicine counseling. This code is specific to PKU only.	V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination		

, , ,	Isoelectric focusing or high	82486	Chromatography, qualitative; column, analyte note elsewhere specified	V78.3	Screening for disorders of blood and blood-	
Various other hemoglobinapathies	performance liquid chromatography or electrophoresis	82491	Chromatography, quantitative, column; single analyte not elsewhere specified, single stationary and mobile phase	\	forming organs; other hemoglobinopathies	
		82664	Electrophorectic technique, not elsewhere specified	V78.8	Screening for disorders of blood and blood-forming organs; other disorders of blood and blood-forming organs  Screening for disorders of blood and blood-forming	
		82728	Ferritin	1		
		83020	Hemoglobin fractionation and quantitation; electrophoresis			
		83021	Hemoglobin fractionation and quantitation; chromatography	V78.9		
		83068	Hemoglobin; unstable, screen		organs; unspecified disorder of blood and	
		83891	Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type		blood-forming organs	
		83892	Molecular diagnostics; enzymatic digestion, each enzyme treatment			
		83894	Molecular diagnostics; separation by gel electrophoresis, each nucleic acid preparation			
		83898	Molecular diagnostics; amplification, target, each nucleic acid sequence			
		83900	Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences			
			83904	Molecular diagnostics; mutation identification by sequencing, single segment, each segment		
					83909	Molecular diagnostics; separation and identification by high resolution technique, each nucleic acid preparation
		83912	Molecular diagnostics; interpretation and report			
		83914	Mutation identification by enzymatic ligation or primer extension, single segment, each segment			
		85660	Sickling of RBC, reduction			
		88184	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker			

					1	
Sic	Sickle cell disease	Isoelectric focusing or high	82486-82489	Chromatography, qualitative; column, analyte note elsewhere specified	V78.2	Special screening for disorders of blood and
		performance liquid chromatography or electrophoresis	82491-82492	Chromatography, quantitative, column; single analyte not elsewhere specified, single stationary and mobile phase	V20 24 V20 22	blood-forming organs; Sickle-cell disease or trait
			83020-83021	(Effective 1/1/2013) - Hemoglobin fractionation and quantitation (eg, A2, S, C, and/or F)	V20.31-V20.32	(Effective 1/1/2013) — Health supervision of infant or child; routine newborn (up to 28 days
			99201-99215	Office visits		old) health check
			99381	Initial preventive visit — infant		,
			99391	Periodic preventive visit — infant	V30.00-V39.01	Newborn(s)
			99401-99404	Preventive medicine counseling		
			\$3850	Genetic testing for sickle cell anemia	V70.0 (Effective 8/1/2011)	Routine general medical exam
					V72.62 (Effective 5/1/2012)	Laboratory examination ordered as part of a routine general medical examination
Pro	prionic acidemia,	Acylcarnitines by	82016	Acylcarnitines; qualitative, each specimen	V77.7	Screening for inborn error
Me	thylmalonic acidemia,	MS/MS	82017	Acylcarnitines; quantitative, each specimen	-	of metabolism
Iso	lonic acidemia, butyrylglycinuria, valeric acidemia, lethylbutyrylglycinuria,		82491	Chromatography, quantitative, column; single analyte not elsewhere specified, single stationary and mobile phase	V77.99	Screening for other and unspecified endocrine, nutritional, metabolic, and immunity disorder
3-M car	3-Methylcrotonyl-CoA carboxylase deficiency, 3-Methylglutaconic aciduria, 3-Hydroxy- 3-methyglutaric aciduria, Holocarboxyl		83788	Mass spectrometry and tandem mass spectrometry (MS, MS/MS), analyte not elsewhere specified; qualitative		
3-n			83789	Mass spectrometry and tandem mass spectrometry (MS, MS/MS), analyte not elsewhere specified; quantitative		
			83919	Organic acids; qualitative, each specimen		

Hearing loss	Otoacoustic emissions and auditory brainstem	92585-92586	Auditory evoked potentials for evoked response audiometry and/or testing of central nervous system	V20.31-V20.32	(Effective 1/1/2013) — Newborn health supervision; up to 28 days old
	response	92587-92588	Evoked otoacoustic emissions		(E((1)0/24/2042)
		99201-99215	Office visits	V30.00-V39.01	(Effective 9/24/2012) — Newborn(s)
		99381	Initial preventive visit — infant	V30.00 V37.01	newborn(3)
		99391	Periodic preventive visit — infant		(Effective 8/1/2011) —
		99401-99404	Preventive medicine counseling	V70.0	Routine general medical exam
				V72.11-V72.19	Examination of ears and hearing

Newborn metabolic screening (Effective 1/1/2011)	Covered through age 2 months	\$3620	Newborn metabolic screening panel, includes test kit, postage, and the laboratory tests specified by the state for inclusion in this panel	V20.0-V20.32 V21.0-V21.9	Well newborn, infant, or child  Child development
		80047	Basic metabolic panel		·
		80048	Basic metabolic panel	V30.00-V39.2	Newborn(s)
		80053	Comprehensive metabolic panel	V70.0 (Effective 8/1/2011)	Routine general medical examination at a health care facility
				V70.3	Other general medical examination for administrative purposes
				V70.5	Health examination of defined subpopulations
				V70.8-V70.9	Other and unspecified general medical examination
				V72.62	Laboratory examination
				V77.0	Screening for thyroid disorders
				V77.3-V77.4	Special screening for endocrine, nutritional, metabolic, and immunity disorders; phenylketonuria (PKU); Screening for galactosemia
				V77.7	Screening for inborn error of metabolism
				V77.99	Screening for other & unspecified endocrine, nutritional, metabolic, and immunity disorder

Newborn metabolic screening, cont.			V78.0-V78.3	Preventive medicine counseling; Special screening for disorders of blood and blood-forming organs- Sickle-cell disease or trait; Screening for disorders of blood and blood-forming organs-other hemoglobinopathies
			V78.8	Screening for disorders of blood and blood-forming organs; other disorders of blood and blood-forming organs

## Guide to Covered Preventive Services Women's Preventive



Service	Patient	Procedure Cod	es	DX Codes	
Well woman visits (Effective 08/01/2012 for	All women	99385-99387	Preventive medicine services, new patient	V10.41	Personal history of malignant neoplasm of cervix uteri
new business reform policies with policy				V16.49	Family history of malignant neoplasm of other genital organ
effective date of 8/1/2012 or later. Effective 01/01/2013		99395-99397	Preventive medicine services, established patient	V70.0	Routine general medical examination at a health care facility
for all reform policies.)		99401-99404	Preventive medicine, individual counseling	V70.3	Other general medical examination for administrative purposes
				V70.5	Health examination of defined subpopulations
				V72.31	Gynecological exam with or without Pap smear
				V73.89	Screening examination for other specified viral diseases
				V76.2	Special screening for malignant neoplasm; cervix
				V76.47	Screening for malignant neoplasms of the vagina

Well woman visits — prenatal or antepartum care	All pregnant women	See Pregnant W	omen section for services		
HPV testing (Effective 08/01/2012 for new business	All women	87620-87622	Infectious agent detection; human papillomavirus	V72.31	(Effective 1/1/2013) — Gynecological exam with or without Pap smear
reform policies with policy effective date of 08/01/2012 or				V70.0	(Effective 1/1/2013) — Routine general medical exam
later. Effective 10/01/2012 for all reform				V73.81	Screening examination for human papillomavirus
policies.)				V73.89	Screening examination for other specified viral diseases
				V76.2	Special screening for malignant neoplasm; cervix
				V76.47	Screening for malignant neoplasms of the vagina
Counseling for sexually transmitted diseases	All women	See Adults or Pr	regnant Women sections for counseling services relate	d to Chlamydia,	Gonorrhea, Syphilis, etc.

Contraceptive methods and counseling  (Effective 08/01/2012 for new business reform policies with policy effective date of 8/1/2012 or later. Effective	11975 11976 11977 11981 11982 11983	Anesthesia for tubal ligation/transection Insertion, implantable contraceptive capsules Removal, implantable contraceptive capsules Removal with reinsertion, implantable contraceptive capsules Insertion, non-biodegradable drug delivery implant Removal, non-biodegradable drug delivery implant	V25.09	contraceptive/family planning counseling  Encounter for counseling on contraceptive management
(Effective 08/01/2012 for new business reform policies with policy effective date of 8/1/2012 or	11977 11981 11982	Removal with reinsertion, implantable contraceptive capsules Insertion, non-biodegradable drug delivery implant		Encounter for counseling on
08/01/2012 for new business reform policies with policy effective date of 8/1/2012 or	11981 11982	contraceptive capsules Insertion, non-biodegradable drug delivery implant		_
reform policies with policy effective date of 8/1/2012 or	11982		V05 44 V05 43	' 3
with policy effective date of 8/1/2012 or		Removal, non-biodegradable drug delivery implant		
effective date of 8/1/2012 or	11983		V25.11-V25.13	Encounter for insertion/ removal of contraceptive device
		Removal with reinsertion, non-biodegradable drug delivery implant		
COLOR ELICOCITO	57170	Diaphragm or cervical cap fitting with instructions	V25.2	Encounter for sterilization
01/01/2013	58300	Insertion of intrauterine device (IUD)		
for all reform policies.)	58301	Removal of intrauterine device (IUD)	V25.3 V25.40-V25.43	Encounter for contraceptive surveillance
poticies.)	58600	Ligation or transection of fallopian tube(s), abdominal or vaginal approach, unilateral or bilateral		
	58605	Ligation or transection of fallopian tube(s), abdominal or vaginal approach, postpartum, unilateral or bilateral, during same hospitalization (separate procedure)	V25.49	surveillance  Encounter for insertion of implantable contraceptive
	58611	Ligation or transection of fallopian tube(s) when done at the time of cesearean delivery or intra- abdominal surgery (list separately in addition to code for primary procedure)	V25.5	Encounter for other specified/unspecified contraceptive management
	58615	Occlusion of fallopian tube(s) by device (e.g., band, clip, Falope ring) vaginal or suprapubic approach	V25.8-V25.9	Presence of intrauterine/ implanted contraceptive device
	58565	Hysteroscopy, surgical; with bilateral fallopian tube cannulation to include occlusion by placement of permanent implants	V45.51-V45.52 V45.59	
	58670	Laparoscopy, surgical; with fulguration of oviducts (with or without transection)		
	58671	Laparoscopy, surgical; with occlusion of oviducts by device (e.g., band, clip, or Falope ring)		
	96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular		
	99201-99215	Office visits		
	99385-99387	Preventive medicine services, new patient		
	99395-99397	Preventive medicine services, established patient		
	99401-99404	Preventive medicine, individual counseling		

Contraceptive	A4261	Cervical cap for contraceptive use	
methods and counseling, cont.	A4264	Permanent implantable contraceptive intratubal occlusion device(s) and delivery system (Essure device)	
	A4266	Diaphragm for contraceptive use	
	J1050	Permanent implantable contraceptive intratubal occlusion device(s) and delivery system (Essure device)	
	J1051	Injection, medroxyprogesterone acetate, 50 mg	
	J1055	Injection, medroxyprogesterone acetate, 150 mg	
	J1056	Injection, medroxyprogesterone acetate/estradiol cypionate, 5 mg/25 mg	
	J7300	Intrauterine copper contraceptive	
	J7302	Levonorgestrel-releasing intrauterine contraceptive system, 52 mg	
	J7303	Contraceptive supply, hormone containing vaginal ring, each	
	J7304	Contraceptive supply, hormone containing patch, each	
	J7306	Levonorgestrel (contraceptive) implant system, including implants and supplies	
	J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	
	S4981	Insertion of levonorgestrel-releasing intrauterine system	
	S4989	Contraceptive intrauterine device (e.g., Progestacert IUD), including implants and supplies	
	S4993	Contraceptive pills for birth control	

	All pregnant or postpartum women	99078	Physician educational services rendered to patients in group setting	V24.1 - V70.0	Lactating mother (supervision of lactation)
		99201-99215	Office visits		
		99401-99404	Preventive medicine counseling		Routine general medical exam
		S9443	Lactation classes, nonphysician provider		
		A4281	Tubing for breast pump, replacement		
		A4282	Adapter for breast pump, replacement		
with policy		A4283	Cap for breast pump bottle, replacement		
effective date of 8/1/2012 or		A4284	Breast shield and splash protector for use with breast pump, replacement		
later. Effective 01/01/2013		A4285	Polycarbonate bottle for use with breast pump, replacement		
for all reform policies.)		A4286	Locking ring for breast pump, replacement		
poticies.)		E0602	Breast pump, manual, any type		
		E0603	Breast pump, electric (AC and/or DC), any type		
		E0604-RR (must have the RR modifier to be covered)	Breast pump, hospital grade, electric (AC and/or DC), any type		
Screening and counseling for interpersonal and domestic violence (Effective 08/01/2012 for new business reform policies with policy effective date of 8/1/2012 or later. Effective 01/01/2013 for all reform policies.)	All women		odes for this. screening and counseling for domestic vio	olence is conside	ered part of the history and